Keystone

FOR LABORATORY RESEARCH USE ONLY.

keystonecompounds.com

CERTIFICATE NO.
PL–26–00024

VERIFICATION KEY
GFEZEMLN

Scan or enter both at prymalab.net/testing/verify

CERTIFICATE OF ANALYSIS · LOT RELEASE · ISSUED FOR KEYSTONE

CJC-1295 (no DAC) / Ipamorelin Blend 10 mg

Lot **PL-2609-024** · Lyophilized co-blend powder · Label claim **10 mg/vial** · Distributed as **CJC-1295 / Ipamorelin (No DAC) 10 mg**

TESTED IN-HOUSE BY PRYMALAB

In-house analytical result, not an independent third-party test

LOT / BATCH NUMBER	DATE MADE	DATE OF ANALYSIS	DATE ISSUED
PL–2609–024	**2026-09-17**	**2026-09-18**	**2026-10-03**
RETEST / EXPIRY	**UNITS IN LOT / SAMPLED**	**STORAGE**	**CERTIFICATE TYPE**
2028-09-17	**250 / 2**	–20 °C, desiccated, dark	Lot COA, 2 pages

COMPOUND
CJC-1295 (no DAC) / Ipamorelin Blend
Modified GRF(1–29) + Ipamorelin co-lyophilized 1:1 blend

CAS NUMBER
863288-34-0 · 170851-70-4

MOLECULAR FORMULA
$C_{152}H_{252}N_{44}O_{42}$ · $C_{38}H_{49}N_9O_5$

THEORETICAL MASS (AVG.)
3367.9 · 711.9 Da (CJC-1295 (no DAC) / Ipamorelin)

COMPOSITION AND SEQUENCES

CJC-1295 (no DAC) 5 mg: H–Y–[D–Ala]–DAIFTQSYRKVLAQLSARKLLQDILSR–NH_2 (29 residues; C–terminal amide) · **Ipamorelin 5 mg**: H–Aib–H–[D–2–Nal]–[D–Phe]–K–NH_2 (5 residues; C–terminal amide)

PURITY · RP-HPLC, AREA %
99.69%
Specification 99.0% (blend, sum of both component peaks)

IDENTITY · OBSERVED MASS
2 / 2
Components confirmed by LC-MS within ± 1.0 Da: 3368.1 / 712.1 Da

OVERALL CONCLUSION
PASS
Meets every specification for the tests performed

TEST	METHOD	SPECIFICATION	RESULT	CONCLUSION
Appearance	Visual inspection	White to off-white lyophilized powder	White lyophilized powder	**PASS**
Identity (mass)	LC-MS, ESI positive	Theoretical ± 1.0 Da, each component	3368.1 Da (CJC-1295 No DAC) · 712.1 Da (Ipamorelin)	**PASS**
Purity	RP-HPLC, UV 214 nm, area%	99.0% (blend)	99.69%	**PASS**
Largest impurity	RP-HPLC, area%	1.0%	0.18% at 7.05 min	**PASS**
Water content	Karl Fischer	5.0%	1.7%	**PASS**
Bacterial endotoxin	LAL, kinetic	≤ 5.0 EU/mg	0.05 EU/mg	**PASS**
Sterility / bioburden	USP <71>, membrane filtration	No growth after 14 days	No growth; conforms	**PASS**

1 HPLC CHROMATOGRAM

Data file: CJI_PL-2609-024_20260918_01 · Column C18, 150 × 4.6 mm · UV 214 nm



Baseline uncropped; both component peaks and impurities labeled with retention times. Peak table on page 2.

For laboratory research use only. Not for human or veterinary use.

2 HPLC METHOD · CJI_PL-2609-024_20260918_01

INSTRUMENT
Waters Alliance e2695, SN E2695B742

DATA SYSTEM
Empower 3, Build 3471

DETECTOR
Waters 2998 PDA

DETECTION WAVELENGTH
214 nm

COLUMN
C18, 150 × 4.6 mm, 3.5 µm

COLUMN PART / SERIAL
186003326 / USHX18211

MOBILE PHASE A
0.1% TFA in water

MOBILE PHASE B
0.1% TFA in MeCN

FLOW RATE
1.0 mL/min

COLUMN TEMPERATURE
30 °C

INJECTION VOLUME
20 µL

RUN TIME
10 min

SAMPLE DILUENT
Water, 0.1% TFA

SAMPLE CONCENTRATION
0.5 mg/mL (blend)

BLANK INJECTED
Yes

REFERENCE STANDARD
In-house CJC/Ipamorelin blend reference, lot PL-RS-CJI-01, component RTs 5.00 / 6.36 min

3 GRADIENT PROGRAM

TIME (MIN)	% A	% B
0.0	95	5
3.0	95	5
7.0	55	45
8.0	20	80
9.0	20	80
10.0	95	5

4 PEAK TABLE

PEAK	RT (MIN)	AREA	AREA %
1	4.18	5,590	0.13
2 (Ipamorelin)	5.02	2,196,010	51.07
3 (CJC-1295 No DAC)	6.38	2,090,660	48.62
4	7.05	7,740	0.18
Total		4,300,000	100.00

Threshold 0.05% area · Blank subtracted: Y · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5 IDENTITY BY MASS SPECTROMETRY

INSTRUMENT
Waters Acquity SQD

IONIZATION / MODE
ESI, positive

OBSERVED M/Z (CHARGE)
712.8 · 734.8 (1+ [M+H]/[M+Na], Ipamorelin) · 1123.7 (3+ [M+3H]) · 843.0 (4+ [M+4H], CJC-1295 No DAC)

DECONVOLUTED MASS
3368.1 / 712.1 Da (by component)

THEORETICAL MASS
3367.9 / 711.9 Da (CJC-1295 No DAC / Ipamorelin)

DIFFERENCE
≤ +0.2 Da (per component)

DATA FILE
CJI_PL-2609-024_MS_20260918_01

ACCEPTANCE
Within ± 1.0 Da (each component)

6 ADDITIONAL TESTS

TEST	PERFORMED BY	DATE	REPORT / FILE
Water content	PrymaLab	2026-09-19	RPT-KF-PL-2609-024
Endotoxin	PrymaLab	2026-09-20	RPT-ET-PL-2609-024
Sterility	PrymaLab	2026-10-02	RPT-ST-PL-2609-024

A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7 REVIEW AND APPROVAL

D. Reynolds
Analyst · performed the testing
Date: 2026-09-18

S. Calloway
Reviewer · checked against raw data
Date: 2026-10-02

M. Phelps
Lab Director · approved for release
Date: 2026-10-03

Raw data retained at: Empower 3 (Build 3471), project PL-2609, archive PL-ARC-2026; 7 years. Outside laboratory reports attached: None

This certificate applies only to the lot named above and describes the units sampled from it; it is not a guarantee for any other lot. Results were obtained by PrymaLab LLC's own laboratory (PrymaLab Analytical) and are not an independent third-party test unless an outside report is attached. This copy is issued for Keystone, a distributor of the lot; the brand shown does not change the laboratory, the method or the results. Reference values (CAS, formula, theoretical mass, sequence) are literature values for the named compound. Authenticity: scan the QR code or enter certificate number PL-26-00024 and key GFEZEMLN at prymalab.net/testing/verify; any copy that does not match the record shown there is not a PrymaLab certificate. PrymaLab LLC products are supplied for laboratory research use only and not for human or veterinary use.